Safety and efficacy of the XIENCE V everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice

The American Journal of Cardiology
Ron WaksmanAugusto D Pichard

Abstract

Data from randomized clinical trials have shown the safety and efficacy of the XIENCE V in selected populations. However, limited data are available comparing the XIENCE V to the first-generation CYPHER sirolimus-eluting stent. This study aimed to assess the long-term safety and clinical efficacy of the XIENCE V everolimus-eluting stent compared to first-generation stents in an unselected patient population. This retrospective analysis included 6,069 patients treated with CYPHER, TAXUS, and XIENCE stents from 2003 to 2009 at our institution. The patients were followed up for ≥1 year after the index procedure. The baseline characteristics were generally comparable among the 3 groups, with the exception of a significantly greater prevalence of diabetes mellitus, systemic hypertension, and a history of angioplasty and coronary bypass surgery among the XIENCE patients. The XIENCE patients also had a twofold greater rate of type C lesions. One-year follow-up data were available for 82% of the patients. The 1-year major adverse cardiovascular events rate was 9.3% for the XIENCE stent versus 9.8% for the CYPHER stent and 11.5% for the TAXUS stent (p = 0.11). Mortality was lower in the XIENCE group than in the CYPHER and TAXUS groups (...Continue Reading

References

Jul 1, 1994·ASAIO Journal : a Peer-reviewed Journal of the American Society for Artificial Internal Organs·R GuidoinJ Awad
Oct 3, 2003·The New England Journal of Medicine·Jeffrey W MosesUNKNOWN SIRIUS Investigators
Dec 7, 2007·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Hana Vaknin-AssaRan Kornowski
May 7, 2010·The New England Journal of Medicine·Gregg W StoneUNKNOWN SPIRIT IV Investigators

❮ Previous
Next ❯

Citations

Feb 12, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jessica A LyndonNick Birbilis
Feb 19, 2014·Expert Opinion on Drug Delivery·Ricardo O EscárcegaRon Waksman
Mar 7, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Minoru IchikawaYoshiyuki Kijima
May 16, 2015·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Hideaki OtaRon Waksman
Apr 15, 2015·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Hideaki OtaRon Waksman
Nov 24, 2012·JACC. Cardiovascular Interventions·Ron Waksman, Israel M Barbash
Feb 10, 2019·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Yuhei NojimaShinsuke Nanto
May 10, 2020·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Yusuke WatanabeAntonio Colombo
Jun 3, 2021·Materials·Alexandru Scafa UdrișteElisabeta Bădilă

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiogenic Shock

Cardiogenic shock is a devastating consequence of acute myocardial infarction and is associated with an extremely high mortality. Here is the latest research.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.